Catalyst overview
Research summary
This catalyst tracks a Phase 2a update for Atebimetinib (IMM-1-104) in 1L Pancreatic cancer. The expected timing is based on the latest available company guidance and may change.
05/15/26:- ASCO June 1 will report 55-patient Ph2a survival data. 05/21/26:- Reported 17.3-mo median OS in Ph2a; full N=55 data at ASCO June 1, 2026. 06/01/26:- Updated Ph2a ASCO data: 55 patients, 17.3-month median overall survival; 36% overall response rate. 08/05/26:- Ph2a ASCO data reiterated. 84% evaluable patients were weight-stable or gained weight.
Verification
Confirm timing and program details against the company announcement or filing.